



Measurement of serum antibodies to Infliximab and Adalimumab

Clinical Policy ID: CCP.1194

Recent review date: 12/2025

Next review date: 4/2027

Policy contains: Adalimumab; anti-drug antibody; immunoassay; immunogenicity; infliximab.

Keystone First VIP Choice has developed clinical policies to assist with making coverage determinations. Keystone First VIP Choice's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Keystone First VIP Choice, on a case by case basis, when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Keystone First VIP Choice's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Keystone First VIP Choice's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Keystone First VIP Choice will update its clinical policies as necessary. Keystone First VIP Choice's clinical policies are not guarantees of payment.

Coverage policy

Measurement of serum anti-drug antibodies to infliximab and adalimumab is clinically proven and, therefore, may be medically necessary for members with active Crohn's disease who meet all of the following criteria (American College of Gastroenterology [Lichtenstein, 2025]):

- Member has documented infliximab or adalimumab drug treatment failure.
- Drug trough levels are subtherapeutic.
- The information will impact clinical management.

For any determinations of medical necessity for medications, refer to the applicable state approved pharmacy policy.

Limitations

All other uses of anti-drug antibody measurement to infliximab and adalimumab are investigational/not clinically proven and, therefore, not medically necessary, including, but not limited to, during induction treatment or proactively irrespective of disease activity status (Feuerstein, 2017; Lichtenstein, 2025).

Alternative covered services

- Serum drug level monitoring.
- Guideline-directed care for chronic inflammatory disorders.

Background

Tumor necrosis factor- α inhibitors can be effective treatment options for patients with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, along with immune disorders such as psoriasis and various forms of arthritis. Infliximab and adalimumab are the most common tumor necrosis factor- α inhibitors. Biosimilars are emerging that expand treatment options for chronic inflammatory conditions and other clinical applications.

However, approximately one-third of patients with immune-mediated inflammatory diseases treated with anti-tumor necrosis factor- α biologic therapies do not respond, and more experience a waning response after initial success. The precise mechanism of a subtherapeutic response has not been fully explained. As monoclonal antibodies, anti-tumor necrosis factor- α inhibitors can elicit an immune response, producing anti-drug antibodies that are associated with reduced or undetectable drug levels, loss of drug efficacy, clinical non-response, and an increased risk of adverse effects (Ogric, 2017). Rates of anti-drug antibodies to infliximab and adalimumab monotherapy are estimated to be 28.0% and 7.5%, respectively, in patients with inflammatory bowel disease (Bots, 2021).

Therapeutic drug monitoring of serum drug levels and anti-drug antibodies has been proposed as means of improving disease management, patient outcomes, and quality of life. Therapeutic drug monitoring may be proactive or reactive. Proactive therapeutic drug monitoring involves measuring serum drug levels and anti-drug antibodies irrespective of disease activity, followed by adjusting drug dosing to achieve pre-specified target serum drug levels. Reactive therapeutic drug monitoring measures drug concentrations and anti-drug antibodies when triggered by a clinical event (Kawano-Dourado, 2024).

Most current anti-drug antibody assays are drug-sensitive and cannot be used close to drug administration when the drug concentration is too high, which may produce false-negative results. To overcome these limitations, new testing methods have been developed that enable anti-drug antibody measurement in the presence of the drug, i.e., drug-tolerant assays. These assays may allow for proactive, early detection of anti-drug antibodies, before a patient experiences clinical symptoms or a loss of response, which, in turn, may predict immunogenicity and drug survival (Martinez-Feito, 2025). This would allow the practitioner to discern the effects of these medications and, potentially, biosimilars, in patients who showed improvement and in those whose benefits have waned over time in a substantial proportion of cases.

Findings

This policy focuses on the clinical benefits of therapeutic drug monitoring using drug-sensitive and drug-tolerant anti-drug antibody assays for patients on infliximab or adalimumab. The following guidelines recommend reactive therapeutic drug monitoring as the standard of care for persons who are failing anti-tumor necrosis factor- α drug treatment, and only testing for the presence of anti-drug antibodies when drug trough levels are low, to aid in understanding the reasons for treatment failure and developing subsequent treatment schedule. There is no consensus on which type of assay to recommend.

The guidelines recommend against therapeutic drug monitoring of anti-drug antibodies as a means of optimizing therapy during induction and preventing future flare-ups and loss of response, or proactively during maintenance treatment. The long-term effects of any changes in clinical management are unknown, and the cost effectiveness

is unclear. The main barrier to anti-drug antibody testing in daily clinical practice is the lack of a universally valid assay and the absence of a cutoff level clearly correlated with a clinical outcome.

Guidelines

The American College of Gastroenterology recommends considering therapeutic drug monitoring to assess anti-tumor necrosis factor- α drug levels and anti-drug antibody status for individuals with documented active Crohn's disease receiving anti-tumor necrosis factor- α therapies, particularly among those who develop secondary loss of response. In this setting, the results could be used to explain the cause of biologic failure (i.e., to differentiate among mechanistic failure, immune-mediated drug failure, and non-immune-mediated drug failure) and guide subsequent treatment decisions. There is insufficient evidence of a clinical benefit to recommend proactive therapeutic drug monitoring for patients on anti-tumor necrosis factor- α treatment for Crohn's disease (Lichtenstein, 2025).

The American Gastroenterological Association Institute guideline (Feuerstein, 2017) conditionally recommends reactive therapeutic drug monitoring in adults with active inflammatory bowel disease treated with anti-tumor necrosis factor- α agents, to guide treatment changes, based on a technical review finding very low-quality supportive evidence, primarily in individuals with Crohn's disease. For adults with quiescent inflammatory bowel disease treated with anti-tumor necrosis factor- α agents, the Association issued no recommendation regarding the use of routine proactive therapeutic drug monitoring, as the overall benefits and potential harms of this strategy remain uncertain (Vande Casteele, 2017).

North American guidelines for rheumatoid arthritis (Fraenkel, 2021) and psoriasis (Menter, 2019) do not address anti-drug antibody testing in the management of these diseases.

Evidence review

The majority of studies evaluating the clinical utility of therapeutic drug monitoring in chronic inflammatory disorders have used only drug-sensitive assays. This limits the ability to assess immunogenicity to when the drug is not measurable in serum. Studies of drug-tolerant assays have emerged that may expand the clinical utility of therapeutic drug monitoring to a proactive role during induction or maintenance treatment, but the clinical benefit is unclear.

The quality of the evidence is low, and results from randomized controlled trials are sparse. The strongest evidence from the following systematic reviews and meta-analyses exists for adults on infliximab treatment for inflammatory bowel disorders, and Crohn's disease, in particular. For patients treated with adalimumab and for children, the evidence was limited in quality and quantity. Studies varied with respect to the type of test used, response criteria, and populations enrolled (Barrau, 2023; Silva-Ferreira, 2016).

Recent systematic reviews and meta-analyses of proactive therapeutic drug monitoring have produced similar findings. In studies of individuals with immune-mediated inflammatory diseases, the majority included adults with inflammatory bowel disease and, to a lesser extent, inflammatory arthritis and psoriasis treated with infliximab. The evidence is insufficient to support the effectiveness of proactive therapeutic drug monitoring of infliximab or adalimumab during induction, or adalimumab during maintenance. Proactive therapeutic drug monitoring with infliximab during maintenance may increase the proportion of patients who experienced sustained disease control or remission, may reduce disease worsening, but may have little or no effect on quality of life, physical function, or mental health. The effects of proactive therapeutic drug monitoring appeared to be consistent across the different immune-mediated diseases. Follow up periods did not exceed one year, making the long term effects of proactive therapeutic drug monitoring uncertain (Zeraatkar, 2024; 10 randomized controlled trials).

In participants with active and quiescent inflammatory bowel disease who received infliximab or adalimumab, proactive therapeutic drug monitoring was not superior to standardized therapy or conventional management for maintaining clinical remission (relative risk 1.16, 95% confidence interval 0.98 to 1.37, n = 528). Limited

observational data suggest it may increase the treatment durability and safety, avoid acute infusion reactions and the appearance of anti-drug antibodies, and reduce the probability of surgery, but long-term results are needed (Manceñido Marcos, 2024).

For patients with inflammatory bowel disease or rheumatoid arthritis receiving adalimumab, a meta-analysis of nine randomized and nonrandomized studies found proactive therapeutic drug monitoring was not superior to reactive therapeutic drug monitoring or conventional management in achieving or maintaining clinical remission (63.42% vs. 55.44%, relative risk 1.24, 95% confidence interval 0.98 to 1.58, four studies). For patients experiencing treatment failure, reactive therapeutic drug monitoring can aid in understanding the reasons for treatment failure and in developing subsequent treatment schedules (Li, 2024; five studies).

Cost effectiveness

A systematic review of six model-based, cost-effectiveness analyses found that therapeutic drug monitoring in people with Crohn's disease treated with infliximab may be cost saving and cost effective compared to standard of care. However, the effectiveness of interventions guided by therapeutic drug monitoring was highly dependent on the clinical management algorithms applied (such as proactive or reflexing testing) (Yao, 2021). In another systematic review, there was insufficient evidence on cost effectiveness to permit conclusions regarding therapeutic drug monitoring in individuals with rheumatoid arthritis (Tikhonova, 2021).

In 2016, we added four peer-reviewed references.

In 2017, we did not identify any newly published systematic reviews, meta-analyses, or guidelines.

In 2018, we updated the references. The policy ID changed from 01.01.03 to CCP.1194.

In 2019, we added one peer-reviewed publication to the reference list.

In 2020, we updated the references. No policy changes are warranted.

In 2021, we updated the references and added no new relevant literature to the policy. No policy changes are warranted.

In 2022, we updated the references and added no new relevant literature to the policy. No policy changes are warranted.

In 2023, we updated the references and added no new relevant literature to the policy. No policy changes are warranted.

In 2024, we found no policy changes were warranted.

In 2025, we updated the references, added several new evidence reviews and guidelines, and deleted older references. We modified coverage to align with guideline recommendations for anti-drug antibody monitoring in persons with active Crohn's disease treated with infliximab or adalimumab.

References

On October 8, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were "serum antibodies," "immunogenicity," "infliximab," and "adalimumab." We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Barrau M, Duprat M, Veyrad P, et al. A systematic review on the interest of drug-tolerant assay in the monitoring of inflammatory bowel disease. *J Crohns Colitis*. 2023;17(4):633-643. Doi: 10.1093/ecco-jcc/jjac164.

Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: A systematic review and meta-analysis. *BioDrugs*. 2021;35(6):715-733. Doi: 10.1007/s40259-021-00507-5.

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology*. 2017;153(3):827-834. Doi: 10.1053/j.gastro.2017.07.032.

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021;73(7):924-939. Doi: 10.1002/acr.24596.

Kawano-Dourado L, Kristianslund EK, Zeraatkar D, et al. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: A clinical practice guideline. *Bmj*. 2024;387:e079830. Doi: 10.1136/bmj-2024-079830.

Li Y, Xie C, Ding X, et al. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? A systematic review and meta-analysis up to 2022. *Front Pharmacol*. 2024;15:1376708. Doi: 10.3389/fphar.2024.1376708.

Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: Management of Crohn's disease in adults. *Am J Gastroenterol*. 2025;120(6):1225-1264. Doi: 10.14309/ajg.0000000000003465.

Manceñido Marcos N, Novella Arribas B, Mora Navarro G, Rodríguez Salvanés F, Loches Belinchón P, Gisbert JP. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis. *Dig Liver Dis*. 2024;56(3):421-428. Doi: 10.1016/j.dld.2023.06.028.

Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: A systematic review. *J Gastroenterol*. 2017;52(1):19-25. Doi: 10.1007/s00535-016-1266-1.

Martinez-Feito A, Novella-Navarro M, Hernandez-Breijo B, et al. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. *Rheumatology (Oxford)*. 2025;64(1):344-351. Doi: 10.1093/rheumatology/kead690.

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072. Doi: 10.1016/j.jaad.2018.11.057.

Mitrev N, Vande Castele N, Seow CH, et al. Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2017;46(11-12):1037-1053. Doi: 10.1111/apt.14368.

Ogric M, Tercelj M, Praprotnik S, et al. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: A comprehensive overview of methodology pitfalls and benefits. *Immunol Res*. 2017;65(1):172-185. Doi: 10.1007/s12026-016-8824-8.

Silva-Ferreira F, Afonso J, Pinto-Lopes P, Magro F. A systematic review on infliximab and adalimumab drug monitoring: Levels, clinical outcomes and assays. *Inflamm Bowel Dis*. 2016;22(9):2289-2301. Doi: 10.1097/MIB.0000000000000855.

Tikhonova IA, Yang H, Bello S, et al. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: A systematic review and economic evaluation. *Health Technol Assess.* 2021;25(8):1-248. Doi: 10.3310/hta25080.

Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. *Gastroenterology.* 2017;153(3):835-857.e836. Doi: 10.1053/j.gastro.2017.07.031.

Zeraatkar D, Pitre TS, Kirsh S, et al. Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: Systematic review and meta-analysis. *BMJ Med.* 2024;3(1):e000998. Doi: 10.1136/bmjmed-2024-000998.

Policy updates

9/2015: initial review date and clinical policy effective date: 1/2016

12/2016: Policy references updated.

12/2017: Policy references updated.

12/2018: Policy references updated. Policy ID changed from 01.01.03 to CCP.1194.

12/2019: Policy references updated.

12/2020: Policy references updated.

12/2021: Policy references updated.

12/2022: Policy references updated.

12/2023: Policy references updated.

12/2024: Policy references updated.

12/2025: Policy references updated. Coverage modified.